IP Library › Granted Patent US 10,526,648
Granted Patent B2
US 10,526,648 · App. 16/033,118 · Granted Jan 7, 2020

Short pendant arm linkers for nucleotides in sequencing applications

Inventors: Elena Cressina (Nr. Saffron Walden, GB); Antoine Francais (Nr. Saffron Walden, GB); Xiaohai Liu (Nr. Saffron Walden, GB)
Assignee: Illumina Cambridge Limited
C12Q1/6869C07H19/073C07H19/14C07H21/04C12Q1/6809C12Q1/6816
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,526,648
App. No.
16/033,118
Granted
Jan 7, 2020
Kind
B2
Abstract

The present disclosure relates to new nucleotide and oligonucleotide compounds and their use in nucleic acid sequencing applications.

Claims (32)

1. A compound of the formula (I):

wherein B is a nucleoside base; and

Fl is a fluorophore attached through an optional linker.

2. The compound according to claim 1 , wherein B is a nucleotide base.

3. The compound according to claim 2 , wherein B is a pyrimidine base.

4. The compound according to claim 3 , wherein the compound is of formula (c) or formula (t):

wherein p is a triphosphate group; and

Fl is a fluorophore attached through an optional linker.

5. The compound according to claim 2 , wherein B is a 7-deazapurine base.

6. The compound according to claim 5 , wherein the compound is of formula (a):

wherein p is a triphosphate group; and

Fl is a fluorophore attached through an optional linker.

7. The compound according to claim 2 , wherein the compound is attached to an oligonucleotide.

8. An oligonucleotide labelled with a compound according to claim 2 .

9. A compound of the formula (II):

wherein B is a nucleotide base.

10. The compound according to claim 9 , wherein B is a pyrimidine base.

11. The compound according to claim 10 , wherein the compound is of formula (ci) or formula (ti):

wherein Oln is an oligonucleotide.

12. The compound according to claim 9 , wherein B is a 7-deazapurine base.

13. The compound according to claim 12 , wherein the compound is of formula (ai):

wherein Oln is an oligonucleotide.

14. An oligonucleotide comprising a compound according to claim 9 .

15. An oligonucleotide comprising two or more copies of a compound according to claim 9 .

16. An oligonucleotide comprising ten or more copies of a compound according to claim 9 .

17. An oligonucleotide comprising one hundred or more copies of a compound according to claim 9 .

18. A kit comprising two or more nucleotides wherein at least one nucleotide is a labelled nucleotide according to claim 2 .

19. The kit according to claim 18 , comprising two or more nucleotides wherein at least two nucleotides are labelled nucleotides according to claim 2 .

20. The kit according to claim 18 , comprising four nucleotides wherein at least two nucleotides are labelled nucleotides according to claim 2 .

21. The nucleotide according to claim 2 , for use in sequencing, expression analysis, hybridization analysis, genetic analysis, RNA analysis, or protein binding assays, or combinations thereof.

22. The oligonucleotide according to claim 8 , for use in sequencing, expression analysis, hybridization analysis, genetic analysis, RNA analysis, or protein binding assays, or combinations thereof.

23. The oligonucleotide according to claim 14 , for use in sequencing, expression analysis, hybridization analysis, genetic analysis, RNA analysis, or protein binding assays, or combinations thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2018
From: CRESSINA, ELENA; FRANCAIS, ANTOINE; LIU, XIAOHAI
To: ILLUMINA CAMBRIDGE LIMITED
Reel/Frame 046956/0683 →
Priority Claims (1)
GB 1711219.4 · Jul 12, 2017 · national
Continuity (1)
Related Publication 20190017111A1 · Jan 17, 2019